Pascal and Francis Bibliographic Databases

Help

Export

Selection :

Permanent link
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19065784

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma : impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

Author
PEGGS, Karl S1 ; SUREDA, Anna1 ; MAHENDRA, Premini1 ; GARCIA-CONDE, Javier1 ; MILLIGAN, Donald1 ; SANZ, Guillermo1 ; THOMSON, Kirsty1 ; ARRANZ, Reyes1 ; GOLDSTONE, Anthony H1 ; ALVAREZ, Ivan1 ; LINCH, David C1 ; SIERRA, Jorge1 ; WENDI QIAN1 ; MACKINNON, Stephen2 ; CABALLERO, Dolores1 ; HUNTER, Ann1 ; URBANO-ISPIZUA, Alvaro1 ; CAVET, James1 ; RIBERA, Josep M1 ; PARKER, Anne1 ; CANALES, Miguel1
[1] Department of Haematology, Royal Free and University College, London, United Kingdom
[2] Department of Haematology, Royal Free and University College, London, United Kingdom
UK and Spanish Collaborative Groups
Source

British journal of haematology. 2007, Vol 139, Num 1, pp 70-80, 11 p ; ref : 1 p.3/4

CODEN
BJHEAL
ISSN
0007-1048
Scientific domain
Medical oncology; Hematology
Publisher
Blackwell, Oxford
Publication country
United Kingdom
Document type
Article
Language
English
Author keyword
Hodgkin lymphoma T-cell depletion allogeneic transplantation reduced intensity
Keyword (fr)
Alemtuzumab Anticorps monoclonal Conditionnement atténué Donneur Déplétion Hodgkin maladie Homogreffe Hématologie Immunisation adoptive Immunothérapie Intensité Long terme Lymphocyte T Pronostic Récidive Résistance traitement Traitement Transfusion lymphocyte donneur Greffe Hémopathie maligne Lymphome Lymphoprolifératif syndrome
Keyword (en)
Alemtuzumab Monoclonal antibody Non myeloablative treatment Donor Depletion Hodgkin disease Homograft Hematology Adoptive immunization Immunotherapy Intensity Long term T-Lymphocyte Prognosis Relapse Treatment resistance Treatment Donor lymphocyte infusion Graft Malignant hemopathy Lymphoma Lymphoproliferative syndrome
Keyword (es)
Alemtuzumab Anticuerpo monoclonal Tratamiento no mieloablativo Donador Depleción Hodgkin enfermedad Homoinjerto Hematología Inmunización adoptiva Inmunoterapia Intensidad Largo plazo Linfocito T Pronóstico Recaida Resistencia tratamiento Tratamiento Injerto Hemopatía maligna Linfoma Linfoproliferativo síndrome
Classification
Pascal
002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis

Discipline
Blood diseases
Origin
Inist-CNRS
Database
PASCAL
INIST identifier
19065784

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS

Access to the document

Searching the Web